GO
Loading...

Amgen Inc

More

  • Early Glance: Biotechnology companies Wednesday, 24 Dec 2014 | 10:23 AM ET

    Amgen Inc. rose $4.40 or 2.8 percent, to $161.92. Biogen Idec rose $4.11 or 1.2 percent, to $339.87. Celgene Corp. rose $3.71 or 3.5 percent, to $109.83.

  • Final Glance: Biotechnology companies Tuesday, 23 Dec 2014 | 6:06 PM ET

    Amgen Inc. fell $7.01 or 4.3 percent, to $157.52. Biogen Idec fell $16.53 or 4.7 percent, to $335.76. Celgene Corp. fell $7.38 or 6.5 percent, to $106.12.

  • Midday Glance: Biotechnology companies Tuesday, 23 Dec 2014 | 1:22 PM ET

    Amgen Inc. fell $9.68 or 5.9 percent, to $154.85. Biogen Idec fell $23.27 or 6.6 percent, to $329.02. Celgene Corp. fell $9.05 or 8.0 percent, to $104.46.

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Final Glance: Biotechnology companies Monday, 22 Dec 2014 | 7:19 PM ET

    Amgen Inc. fell $5.64 or 3.3 percent, to $164.53. Biogen Idec fell $8.38 or 2.3 percent, to $352.29. Celgene Corp. fell $3.68 or 3.1 percent, to $113.50.

  • Dec 22- The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's treatments after trying for nearly a year to win a deeper discount. Express Scripts' move reignited investor concerns that pharmaceutical companies...

  • Midday Glance: Biotechnology companies Monday, 22 Dec 2014 | 1:22 PM ET

    Amgen Inc. fell $3.99 or 2.3 percent, to $166.18. Biogen Idec fell $4.67 or 1.3 percent, to $356.00. Celgene Corp. fell $2.48 or 2.1 percent, to $114.70.

  • Early Glance: Biotechnology companies Monday, 22 Dec 2014 | 10:22 AM ET

    Amgen Inc. fell $3.09 or 1.8 percent, to $167.08. Biogen Idec fell $8.52 or 2.4 percent, to $352.15. Celgene Corp. fell $2.48 or 2.1 percent, to $114.70.

  • Final Glance: Biotechnology companies Friday, 19 Dec 2014 | 6:41 PM ET

    Amgen Inc. rose $1.69 or 1.0 percent, to $170.17. Biogen Idec rose $6.97 or 2.0 percent, to $360.67. Celgene Corp. rose$. 70 or. 6 percent, to $117.18.

  • Dec 19- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after the treatment was approved by the European Commission. AstraZeneca expects potential sales of around $2 billion a year from the drug. London- based AstraZeneca's U.S.-listed shares were down about 1 percent at $71.41 in afternoon...

  • Midday Glance: Biotechnology companies Friday, 19 Dec 2014 | 1:25 PM ET

    Amgen Inc. rose$. 07 or percent, to $168.55. Biogen Idec rose $4.57 or 1.3 percent, to $358.27. Celgene Corp. rose$. 44 or. 4 percent, to $116.92.

  • Early Glance: Biotechnology companies Friday, 19 Dec 2014 | 10:20 AM ET

    Amgen Inc. fell$. 37 or. 2 percent, to $168.11. Biogen Idec fell $3.70 or 1.0 percent, to $350.00. Celgene Corp. rose$. 12 or. 1 percent, to $116.60.

  • Final Glance: Biotechnology companies Thursday, 18 Dec 2014 | 8:08 PM ET

    Amgen Inc. rose $5.00 or 3.1 percent, to $168.48. Biogen Idec rose $20.81 or 6.3 percent, to $353.70. Celgene Corp. rose $3.66 or 3.2 percent, to $116.48.

  • Midday Glance: Biotechnology companies Thursday, 18 Dec 2014 | 1:48 PM ET

    Amgen Inc. rose $3.32 or 2.0 percent, to $166.80. Biogen Idec rose $15.05 or 4.5 percent, to $347.94. Celgene Corp. rose $2.68 or 2.4 percent, to $115.50.

  • Early Glance: Biotechnology companies Thursday, 18 Dec 2014 | 11:11 AM ET

    Amgen Inc. rose $2.18 or 1.3 percent, to $165.66. Biogen Idec rose $12.84 or 3.9 percent, to $345.73. Celgene Corp. rose $2.63 or 2.3 percent, to $115.45.

  • Final Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 7:08 PM ET

    Amgen Inc. rose $4.04 or 2.5 percent, to $163.48. Biogen Idec rose $7.76 or 2.4 percent, to $332.89. Celgene Corp. rose $2.73 or 2.5 percent, to $112.82.

  • Leaked Sony emails show Loeb influence on studio execs Wednesday, 17 Dec 2014 | 3:11 PM ET

    TOKYO/ BOSTON, Dec 17- Sony Corp movie executives kept up a dialogue with hedge fund titan Daniel Loeb, even after rebuffing the billionaire investor's proposal to sell up to one-fifth of the studio's entertainment business, leaked emails show. Loeb's New York- based Third Point took a 7 percent stake in the company in May 2013 and suggested that proceeds from a...

  • Midday Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 1:17 PM ET

    Amgen Inc. rose $1.41 or. 9 percent, to $160.85. Biogen Idec rose $2.00 or. 6 percent, to $327.13. Celgene Corp. rose$. 63 or. 6 percent, to $110.72.

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...